Helenine was first obtained by Shope (1) in 1948 from Penicillium funiculosum. It has been reported to protect mice against swine influenza, Columbia SK encephalomyelitis, and Semliki Forest viruses (2, 3), and to prevent the development of poliomyelitis in monkeys (4); the protection was apparently achieved without adverse side effects. It has been briefly reported by Gitterman to inhibit the cytopathogenic effect of Semliki Forest virus grown in chick embryo fibroblast cell culture (5).
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(Received for publication 4 November 1965) Helenine was first obtained by Shope (1) in 1948 from Penicillium funiculosum. It has been reported to protect mice against swine influenza, Columbia SK encephalomyelitis, and Semliki Forest viruses (2, 3) , and to prevent the development of poliomyelitis in monkeys (4); the protection was apparently achieved without adverse side effects. It has been briefly reported by Gitterman to inhibit the cytopathogenic effect of Semliki Forest virus grown in chick embryo fibroblast cell culture (5) .
Obviously, isolation of helenine is of great interest in both practical and theoretical virology; however, a serious effort of Lewis et al. has resulted only in partial purification (6) . One major difficulty was the wide fluctuation in antiviral activity of various crude helenine preparations freshly harvested from peniclllium cultures grown under presumably identical conditions. In our present attempt to isolate helenine we were working on the hypothesis that an inhibitor to the antiviral agent is present in penicillium culture. The hypothesis was suggested by our recent findings with Semliki Forest virus: titers of viral hemagglutinin in fresh homogenates obtained by identical procedures from baby mouse brain infected with the virus varied from 0 to 16 (7) and a small molecule inhibitor to the hemagglutinin was present in the infected brain preparations (8) .
The present report describes a test of the hypothesis that an inhibitor to helenine may be present in the peniclllium cultures. If a helenine preparation should contain an inhibitor, dilution of the preparation would decrease the concentration of the inhibitor as well as of the active principle. Hence, one would expect antiviral activity to vary with dilution according to the following pattern: Within the effective concentration range of the inhibitor, the decreases in antiviral activity should be smaller than one would expect from the dilution ratios. When further dilution has reduced inhibitor concentrations below effective levels, antiviral activity will be decreased more rapidly, in proportion to the dilution ratio. Hence, variation of activity with dilution provides a test for the * Present address: Bio-Medical Division, University of California, Livermore. 50S
inhibitor hypothesis. Our results confirm this hypothesis and offer a new lead to the isolation of helenine.
RESULTS
A freshly prepared crude helenine preparation was titrated at serial 2-fold dilutions for its activity to inhibit plaque formation in mouse L cell layer by Semliki Forest virus according to a procedure to be described later (9) . In essence, this consists in pretreatment of the L cell layer for 21 hr with helenine before inoculation with virus.
The results are given by the curve labeled "Whole Suspension" in Fig. 1 . Dilution of the preparation up to 8-fold resulted in a steady decrease, rather than an increase in the plaque number; i.e., antiviral activity increased with the dilution. After a short leveling off between the 8-and 16-fold dilution points, the curve assumed a linear upward trend with a marked increase in steepness after the 128-fold dilution point. The results are consistent with the inhibitor hypothesis described above.
To ascertain if the inhibitor can be separated from helenine by centrifugation, 100 ml of the same helenine preparation was centrifuged (10 ml per tube) with a Spinco Model L ultracentrifuge in a No. 40 rotor for 2 hr at 40,000 l~P~ at 4-8°C. The resulting slightly reddish pellets were resuspended in 1% of the original volume in a solution of 0.15 M NaC1, 0.01 ~ sodium phosphates, and 0.0001 MgC12, pH 7.0, followed by gentle stirring for 0.5 hr at 2-4°C. The resulting suspension was then assayed for plaque-inhibiting activity, together with the supernatant, on portions of the same batch of fresh L cell monolayers as was used for the assay of the whole suspension. The whole suspension, as well as the supernatant, was stirred before assay under the same conditions as those employed for the pellet suspension. It has been found that the stirring did not produce a change in the antiviral activity of the whole suspension.
The results are also shown in Fig. 1 . The curve for the supernatant shows no reduction in plaque number through the entire concentration range corresponding to the inhibition-to-helenine and inhibition-free zones for the whole suspension. On the other hand, the pellet curve shows the reduction at all the dilutions studied. When the pellets were diluted to volumes 0.2 to 0.8 of the original volume of whole suspension, less than one plaque per Petri dish, or 0.08 % of the number observed for whole suspension was seen. Further dilution resulted in a steady increase in plaque number. The slope of the dilution curve between 3.2-and 25.6-fold dilution points is similar to that of the whole suspension at the inhibition-free zone. Therefore, inhibition to helenine was not observed with the pellet. In other words, helenine free of inhibition can be obtained by the ultracentrifugation.
These results are consistent with the interpretation that the inhibitor is a molecule much smaller than helenine. However, they do not exclude the possi-bility that the inhibitor was sedimented and inactivated by the ultracentrifugation.
A 20% reduction in plaque number occurred at the 25.8-fold dilution of the pellet. Since the same reduction was observed at about the 516-fold dilution 1 . Dependence of number of Semliki Forest virus (SFV) plaques upon dilution. Three helenine samples were used to pretreat L cell layers; whole suspension, supernatant, and pellet. Values of 132 and ll9 plaques were obtained with duplicate assays in cell layers treated with the diluent. The 1-fold dilution point for the pellet preparation is that in which it was suspended in a volume equivalent to that of the whole suspension from which it was derived. of the uncentrifuged sample in the inhibition-free zone, it is thus concluded that after the centrifugation only about 5 % of the activity was recovered in the pellet. It appears probable at first glance that the rest of the activity still remains with the supernatant but is masked by the inhibitor. However, this is shown to be unlikely by the finding that no helenine activity was observed with the supernatant even at dilutions corresponding to the inhibition-free zone of the uncentrifuged sample. The loss of activity was very likely a result of the pelleting of helenine. Hence, although the discovery of the inhibitor exposes the weakness of the previous experimental basis for the claim of Lewis et al. that all helenine is sedimented by ultracentrifugation (6), the results of our centrifugafion study nevertheless substantiate this claim.
SUMMARy
The present findings indicate that the wide fluctuation observed in the antiviral activity of various crude helenine preparations may be attributable to the presence of varying amounts of inhibitor. Antiviral activity could be enhanced by removal of the inhibitor. A meaningful value for helenine fiter in a preparation clearly should be determined in the inhibitor-free zone.
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